We use cookies to enhance the usability of our website. If you continue, we'll assume that you are happy to receive all cookies. More information. Don't show this again.
UTERINE CORPUS ENDOMETRIAL CARCINOMA (TCGA) - Interactive survival scatter ploti
The Survival Scatter plot shows the clinical status (i.e. dead or alive) for all individuals in the patient cohort, based on the same data that underlies the corresponding Kaplan-Meier plots. Patients that are alive at last time for follow-up are shown in blue and patients who have died during the study are shown in red.
The x-axis shows the expression levels (FPKM) of the investigated gene in the tumor tissue at the time of diagnosis. The y-axis shows the follow-up time after diagnosis (years). Both axes are complimented with kernel density curves demonstrating the data density over the axes. The top density plot shows the expression levels (FPKM) distribution among dead (red) and alive patients (blue). The right density plot shows the data density of the survived years of dead patients with high and low expression levels respectively, stratified using the cutoff indicated by the vertical dashed line through the Survival Scatter plot. This cutoff is automatically defined based on the FPKM cutoff that minimizes the p-score. The cutoff can be changed by dragging the vertical line or by entering a cutoff value in the square labeled "Current cut-off".
Under the Survival Scatter plot the p-score landscape (black curve; left axis) is shown together with dead median separation (red curve; right axis). Dead median separation is the difference in median mRNA expression between patients who have died with high and low expression, respectively. It is calculated as follows: median FPKM expression of dead patients with high expression - median FPKM expression of dead patients with low expression. This is intended to aid the user in visually exploring custom cutoffs and the associated p-scores and dead median separation.
Individual patient data is displayed and can be filtered by clicking on one or more of the category buttons on the top of the page. Categories describing expression level and patient information include: high, low, alive, dead, female, male and tumor stages. The scale of the x-axis can be toggled between linear and log-scale by clicking on the "x log" button. Mouse-over function shows TCGA ID, patient information and mRNA expression (FPKM) for each patient.
& Survival analysisi
Kaplan-Meier plots summarize results from analysis of correlation between mRNA expression level and patient survival. Patients were divided based on level of expression into one of the two groups "low" (under cut off) or "high" (over cut off). X-axis shows time for survival (years) and y-axis shows the probability of survival, where 1.0 corresponds to 100 percent.
SERINC1 is not prognostic in Uterine Corpus Endometrial Carcinoma (TCGA)
Stage:
Survival analysis
Current cut offi
Current cut-off shows the cut-off (FPKM) currently selected. It may be changed manually. When the current cut-off is changed, the vertical dashed line indicating cut-off, the interactive survival scatter plot and the Kaplan-Meier curve will be automatically adjusted to show results accordingly.
:
Best expression cut offi
Based on the FPKM value of each gene, patients were classified into two groups and association between prognosis (survival) and gene expression (FPKM) was examined. The best expression cut-off refers the FPKM value that yields maximal difference with regard to survival between the two groups at the lowest log-rank P-value. Best expression cut-off was selected based on survival analysis .
When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the best expression cut-off.
Median expression refers to the median FPKM value calculated based on the gene expression (FPKM) data from all patients in this dataset. When clicking on this number, the vertical dashed line indicating cut-off, the interactive survival plot, and the Kaplan-Meier curve will be adjusted to show results based on the median expression.
Median follow up time refers to the median time (years) after diagnosis with this type of cancer, based on clinical data from all patients in this dataset.
: N/A
P scorei
Log-rank P value for Kaplan-Meier plot showing results from analysis of correlation between mRNA expression level and patient survival.
N/A
5-year survival highi
5-year survival for patients with higher expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
5-year survival lowi
5-year survival for patients with lower expression than the expression cutoff.
For melanoma and glioma, 3-year survival is shown.
N/A
TCGA RNA samplesi
RNA-seq data is reported as average FPKM (number Fragments Per Kilobase of exon per Million reads), generated by the The Cancer Genome Atlas (TCGA) .
Normal distribution across the dataset is visualized with box plots, shown as median and 25th and 75th percentiles. Points are displayed as outliers if they are above or below 1.5 times the interquartile range. FPKM values of the individual samples are presented next to the box plot.
Average TPM
36.7
Number of samples
176
Samples
Sample
Description
TPM
TCGA-BK-A4ZD-01A
0 years, female, black or african american, stage:Stage IA, alive, 506 days
107.0
TCGA-BK-A6W4-01A
0 years, female, black or african american, stage:Stage IA, alive, 300 days
93.6
TCGA-BK-A139-01A
0 years, female, white, stage:Stage IB, dead, 943 days
91.4
TCGA-AX-A3FS-01A
0 years, female, white, stage:Stage IA, alive, 7 days
90.3
TCGA-EY-A3L3-01A
0 years, female, black or african american, stage:Stage IA, alive, 832 days
89.9
TCGA-AJ-A3NF-01A
0 years, female, white, stage:Stage IIIC, alive, 645 days
88.9
TCGA-PG-A914-01A
0 years, female, black or african american, stage:Stage IA, alive, 687 days
86.1
TCGA-EY-A54A-01A
0 years, female, black or african american, stage:Stage IIIC, alive, 447 days
80.4
TCGA-AJ-A6NU-01A
0 years, female, black or african american, stage:Stage II, alive, 632 days
79.5
TCGA-A5-AB3J-01A
0 years, female, black or african american, stage:Stage II, alive, 512 days
77.5
TCGA-AJ-A3OJ-01A
0 years, female, white, stage:Stage II, alive, 467 days
77.4
TCGA-AX-A3GI-01A
0 years, female, black or african american, stage:Stage IIIC, alive, 12 days
72.5
TCGA-D1-A3JP-01A
0 years, female, white, stage:Stage IA, alive, 515 days
72.4
TCGA-4E-A92E-01A
0 years, female, black or african american, stage:Stage I, alive, 13 days
71.5
TCGA-A5-A3LP-01A
0 years, female, white, stage:Stage IB, alive, 455 days
68.4
TCGA-KP-A3W4-01A
0 years, female, white, stage:Stage IIIA, dead, 554 days
67.7
TCGA-EY-A1GP-01A
0 years, female, black or african american, stage:Stage IA, alive, 573 days
67.2
TCGA-DF-A2KR-01A
0 years, female, stage:Stage IIIC, alive, 1865 days
65.0
TCGA-AX-A3FZ-01A
0 years, female, white, stage:Stage IIIB, alive, 6 days
64.9
TCGA-B5-A5OC-01A
0 years, female, black or african american, stage:Stage IIIB, alive, 1249 days
61.9
TCGA-BK-A0CA-01A
0 years, female, white, stage:Stage IIIC, alive, 1064 days
61.8
TCGA-BK-A6W3-01A
0 years, female, black or african american, stage:Stage II, alive, 305 days
60.8
TCGA-A5-A2K4-01A
0 years, female, white, stage:Stage IIIA, dead, 871 days
60.1
TCGA-A5-A2K2-01A
0 years, female, white, stage:Stage IA, alive, 3595 days
59.9
TCGA-AJ-A3EK-01A
0 years, female, white, stage:Stage IA, alive, 446 days
59.2
TCGA-EY-A1GO-01A
0 years, female, white, stage:Stage IIIC, alive, 586 days
59.2
TCGA-PG-A917-01A
0 years, female, black or african american, stage:Stage IA, alive, 212 days
59.2
TCGA-AJ-A5DW-01A
0 years, female, black or african american, stage:Stage IA, alive, 390 days
58.2
TCGA-EO-A22X-01A
0 years, female, stage:Stage IIIA, alive, 1752 days
57.7
TCGA-KP-A3VZ-01A
0 years, female, white, stage:Stage IV, alive, 722 days
57.4
TCGA-QS-A744-01A
0 years, female, black or african american, stage:Stage IIIB, alive, 451 days
56.7
TCGA-PG-A5BC-01A
0 years, female, black or african american, stage:Stage II, alive, 707 days
56.6
TCGA-AJ-A3NE-01A
0 years, female, white, stage:Stage IA, alive, 628 days
55.6
TCGA-D1-A3DA-01A
0 years, female, white, stage:Stage IIIC, alive, 483 days
54.6
TCGA-E6-A2P8-01A
0 years, female, black or african american, stage:Stage IV, dead, 72 days
54.5
TCGA-A5-A7WJ-01A
0 years, female, black or african american, stage:Stage IA, alive, 341 days
53.7
TCGA-AJ-A3BG-01A
0 years, female, white, stage:Stage IA, alive, 550 days
52.8
TCGA-AJ-A3QS-01A
0 years, female, black or african american, stage:Stage IIIA, alive, 513 days
52.2
TCGA-EO-A3B1-01A
0 years, female, stage:Stage IB, alive, 820 days
51.9
TCGA-AJ-A23N-01A
0 years, female, white, stage:Stage IIIA, dead, 439 days
51.4
TCGA-AX-A3G1-01A
0 years, female, white, stage:Stage IC, dead, 624 days
50.0
TCGA-AJ-A3NH-01A
0 years, female, white, stage:Stage IB, dead, 1 days
49.9
TCGA-AX-A2IN-01A
0 years, female, white, stage:Stage IC, dead, 947 days
49.0
TCGA-BG-A3EW-01A
0 years, female, white, stage:Stage III, alive, 344 days
48.0
TCGA-PG-A915-01A
0 years, female, black or african american, stage:Stage IA, alive, 249 days
47.8
TCGA-B5-A3S1-01A
0 years, female, white, stage:Stage IIIC, alive, 902 days
47.3
TCGA-EO-A3AU-01A
0 years, female, stage:Stage II, alive, 1543 days
47.2
TCGA-DI-A1BU-01A
0 years, female, white, stage:Stage IIB, alive, 1195 days
47.1
TCGA-KP-A3W0-01A
0 years, female, stage:Stage IB, alive, 404 days
46.7
TCGA-DF-A2KN-01A
female, stage:Stage IC, alive, 67 days
46.2
TCGA-B5-A1MW-01A
0 years, female, white, stage:Stage IA, alive, 447 days
45.9
TCGA-A5-A1OH-01A
0 years, female, white, stage:Stage IIIA, alive, 1105 days
45.7
TCGA-EO-A22Y-01A
0 years, female, white, stage:Stage IA, alive, 1567 days
45.5
TCGA-KJ-A3U4-01A
0 years, female, white, stage:Stage IA, alive, 1095 days
45.2
TCGA-EY-A549-01A
0 years, female, black or african american, stage:Stage IA, alive, 605 days
45.1
TCGA-D1-A3JQ-01A
0 years, female, white, stage:Stage IIIC, alive, 526 days
44.7
TCGA-AJ-A3IA-01A
0 years, female, white, stage:Stage IB, alive, 633 days
44.0
TCGA-EY-A1GL-01A
0 years, female, white, stage:Stage II, alive, 1014 days
43.7
TCGA-EO-A3KX-01A
0 years, female, white, stage:Stage IA, alive, 1170 days
43.7
TCGA-EO-A22U-01A
0 years, female, white, stage:Stage IB, alive, 1407 days
43.6
TCGA-5B-A90C-01A
0 years, female, black or african american, stage:Stage IA, alive, 1202 days
43.1
TCGA-D1-A3DH-01A
0 years, female, white, stage:Stage IA, alive, 573 days
42.7
TCGA-EO-A3B0-01A
0 years, female, asian, stage:Stage IIIC, alive, 1412 days
42.3
TCGA-EY-A4KR-01A
0 years, female, black or african american, stage:Stage IIIC, dead, 346 days
41.9
TCGA-A5-A3LO-01A
0 years, female, white, stage:Stage IB, alive, 776 days
41.9
TCGA-EY-A2ON-01A
0 years, female, black or african american, stage:Stage IVB, dead, 610 days
41.8
TCGA-B5-A3FA-01A
0 years, female, white, stage:Stage IC, alive, 2929 days
41.8
TCGA-AJ-A3NC-01A
0 years, female, white, stage:Stage IA, alive, 1125 days
41.3
TCGA-B5-A3F9-01A
0 years, female, black or african american, stage:Stage IB, alive, 4155 days
41.2
TCGA-EO-A3KW-01A
0 years, female, stage:Stage IA, alive, 497 days
41.0
TCGA-EY-A72D-01A
0 years, female, black or african american, stage:Stage II, alive, 179 days
40.3
TCGA-AJ-A5DV-01A
0 years, female, black or african american, stage:Stage IA, alive, 679 days
39.6
TCGA-EY-A2OQ-01A
0 years, female, white, stage:Stage IA, alive, 885 days
39.4
TCGA-AJ-A2QM-01A
0 years, female, white, stage:Stage II, alive, 894 days
39.4
TCGA-B5-A0K9-01A
0 years, female, white, stage:Stage II, dead, 409 days
38.5
TCGA-AJ-A3OK-01A
0 years, female, white, stage:Stage IA, alive, 485 days
38.1
TCGA-EO-A3L0-01A
0 years, female, white, stage:Stage IA, alive, 1554 days
37.8
TCGA-AJ-A3OL-01A
0 years, female, white, stage:Stage IIIA, dead, 449 days
37.6
TCGA-AX-A3G4-01A
0 years, female, native hawaiian or other pacific islander, stage:Stage IIIC, alive, 9 days
37.4
TCGA-D1-A3DG-01A
0 years, female, white, stage:Stage IVB, dead, 130 days
37.3
TCGA-EO-A3KU-01A
0 years, female, stage:Stage II, alive, 677 days
37.1
TCGA-AX-A3FT-01A
0 years, female, white, stage:Stage IB, alive, 6 days
37.1
TCGA-BG-A0MK-01A
0 years, female, black or african american, stage:Stage IIB, dead, 1317 days
36.4
TCGA-AJ-A8CT-01A
0 years, female, black or african american, stage:Stage IA, alive, 82 days
36.4
TCGA-B5-A5OE-01A
0 years, female, black or african american, stage:Stage IIIC, alive, 1063 days
36.3
TCGA-EY-A3QX-01A
0 years, female, white, stage:Stage IVB, dead, 989 days
36.0
TCGA-B5-A3FC-01A
0 years, female, black or african american, stage:Stage II, alive, 2185 days
35.7
TCGA-B5-A3FH-01A
0 years, female, black or african american, stage:Stage IA, alive, 841 days
35.7
TCGA-B5-A0JN-01A
0 years, female, black or african american, stage:Stage IVB, alive, 1939 days
35.0
TCGA-AJ-A2QO-01A
0 years, female, white, stage:Stage IB, dead, 1045 days
34.7
TCGA-FI-A3PX-01A
0 years, female, white, stage:Stage IIIC, alive, 2384 days
34.7
TCGA-PG-A7D5-01A
0 years, female, black or african american, stage:Stage IA, alive, 1177 days
34.7
TCGA-SJ-A6ZI-01A
0 years, female, black or african american, stage:Stage IB, alive, 631 days
34.5
TCGA-AJ-A3TW-01A
0 years, female, white, stage:Stage IB, alive, 513 days
33.9
TCGA-BG-A3PP-01A
0 years, female, white, stage:Stage II, alive, 681 days
33.6
TCGA-BK-A13B-01A
0 years, female, black or african american, stage:Stage IB, alive, 966 days
33.2
TCGA-KP-A3W1-01A
0 years, female, stage:Stage IA, alive, 288 days
33.1
TCGA-PG-A916-01A
0 years, female, black or african american, stage:Stage I, alive, 522 days
33.0
TCGA-AJ-A3BF-01A
0 years, female, white, stage:Stage IIIC, alive, 551 days
32.6
TCGA-AJ-A3EJ-01A
0 years, female, white, stage:Stage IIIC, dead, 50 days
31.4
TCGA-AJ-A3EL-01A
0 years, female, native hawaiian or other pacific islander, stage:Stage IA, alive, 684 days
31.2
TCGA-AX-A2HH-01A
0 years, female, white, stage:Stage IA, alive, 540 days
30.9
TCGA-BK-A56F-01A
0 years, female, black or african american, stage:Stage IB, alive, 401 days
30.8
TCGA-E6-A2P9-01A
0 years, female, white, stage:Stage IA, alive, 1386 days
30.7
TCGA-B5-A0JR-01A
0 years, female, white, stage:Stage IB, alive, 1731 days
30.7
TCGA-SL-A6JA-01A
0 years, female, black or african american, stage:Stage IB, alive, 7 days
30.4
TCGA-A5-A7WK-01A
0 years, female, black or african american, stage:Stage IA, alive, 560 days
30.4
TCGA-AJ-A3NG-01A
0 years, female, white, stage:Stage II, alive, 475 days
30.2
TCGA-AJ-A8CW-01A
0 years, female, black or african american, stage:Stage IA, alive, 4 days
30.2
TCGA-AJ-A3I9-01A
0 years, female, white, stage:Stage II, dead, 519 days
29.4
TCGA-E6-A8L9-01A
0 years, female, black or african american, stage:Stage IB, alive, 1013 days
29.4
TCGA-QF-A5YS-01A
0 years, female, black or african american, stage:Stage II, alive, 689 days
29.1
TCGA-DF-A2KY-01A
0 years, female, stage:Stage IVA, alive, 332 days
28.0
TCGA-KP-A3W3-01A
0 years, female, white, stage:Stage IB, alive, 794 days
27.4
TCGA-FI-A3PV-01A
0 years, female, black or african american, stage:Stage IA, dead, 1249 days
27.1
TCGA-B5-A3FD-01A
0 years, female, black or african american, stage:Stage IA, dead, 1197 days
26.3
TCGA-EY-A1GX-01A
0 years, female, white, stage:Stage IIIA, dead, 1127 days
25.7
TCGA-AX-A2H4-01A
0 years, female, white, stage:Stage IIIA, dead, 916 days
25.3
TCGA-EY-A2OP-01A
0 years, female, white, stage:Stage IA, alive, 944 days
24.8
TCGA-2E-A9G8-01A
0 years, female, black or african american, stage:Stage III, alive, 1249 days
24.7
TCGA-AJ-A3EM-01A
0 years, female, white, stage:Stage IB, alive, 677 days
24.5
TCGA-PG-A6IB-01A
0 years, female, black or african american, stage:Stage IA, alive, 648 days
24.4
TCGA-DF-A2KZ-01A
0 years, female, stage:Stage IB, alive, 826 days
24.3
TCGA-D1-A2G0-01A
0 years, female, white, stage:Stage IB, alive, 1484 days
23.8
TCGA-AJ-A8CV-01A
0 years, female, black or african american, stage:Stage IB, alive, 1068 days
23.5
TCGA-K6-A3WQ-01A
0 years, female, white, stage:Stage IVB, dead, 427 days
23.0
TCGA-EY-A548-01A
0 years, female, black or african american, stage:Stage IA, alive, 430 days
22.8
TCGA-B5-A11R-01A
0 years, female, black or african american, stage:Stage II, alive, 2349 days
22.6
TCGA-B5-A3FB-01A
0 years, female, black or african american, stage:Stage IB, alive, 2844 days
21.9
TCGA-AX-A3G6-01A
0 years, female, white, stage:Stage IA, alive, 8 days
21.5
TCGA-QF-A5YT-01A
0 years, female, black or african american, stage:Stage II, alive, 1215 days
20.8
TCGA-B5-A5OD-01A
0 years, female, black or african american, stage:Stage IIIC, alive, 1038 days
20.1
TCGA-EY-A210-01A
0 years, female, black or african american, stage:Stage IIIC, alive, 383 days
19.9
TCGA-EO-A3AS-01A
0 years, female, stage:Stage IA, alive, 1046 days
19.8
TCGA-DI-A2QY-01A
0 years, female, white, stage:Stage IIB, dead, 3349 days
19.2
TCGA-AX-A3G3-01A
0 years, female, white, stage:Stage IIIA, alive, 42 days
18.9
TCGA-AP-A3K1-01A
0 years, female, white, stage:Stage IVB, dead, 666 days
18.1
TCGA-JU-AAVI-01A
0 years, female, black or african american, stage:Stage IIIC, dead, 540 days
18.0
TCGA-AX-A3FW-01A
0 years, female, white, stage:Stage IB, alive, 17 days
17.5
TCGA-EO-A3AV-01A
0 years, female, stage:Stage IIIC, alive, 1069 days
17.4
TCGA-QS-A5YR-01A
0 years, female, black or african american, stage:Stage IIIB, alive, 719 days
17.0
TCGA-EY-A2OO-01A
0 years, female, white, stage:Stage IB, alive, 1392 days
16.9
TCGA-AP-A5FX-01A
0 years, female, black or african american, stage:Stage IIIC, dead, 1099 days
16.5
TCGA-DI-A2QT-01A
0 years, female, american indian or alaska native, stage:Stage IIIC, dead, 377 days
16.1
TCGA-SL-A6J9-01A
0 years, female, black or african american, stage:Stage IB, alive, 2 days
15.8
TCGA-DI-A1C3-01A
0 years, female, white, stage:Stage IB, alive, 739 days
15.1
TCGA-EY-A5W2-01A
0 years, female, black or african american, stage:Stage IB, alive, 516 days
14.7
TCGA-AX-A3GB-01A
0 years, female, white, stage:Stage IB, alive, 440 days
14.5
TCGA-DF-A2KV-01A
0 years, female, stage:Stage IB, alive, 2717 days
13.9
TCGA-AJ-A3BK-01A
0 years, female, white, stage:Stage IC, alive, 1031 days
12.8
TCGA-EO-A1Y7-01A
0 years, female, stage:Stage IB, alive, 1495 days
11.0
TCGA-A5-A2K7-01A
0 years, female, stage:Stage II, alive, 1063 days
10.2
TCGA-A5-A2K3-01A
0 years, female, white, stage:Stage IA, alive, 2012 days
10.1
TCGA-AX-A3G9-01A
0 years, female, white, stage:Stage IIIC, alive, 558 days
9.5
TCGA-AX-A05W-01A
0 years, female, white, stage:Stage IIB, alive, 2450 days
9.1
TCGA-QS-A8F1-01A
0 years, female, black or african american, stage:Stage IIIA, dead, 135 days
9.0
TCGA-DF-A2KU-01A
female, stage:Stage IB, alive, 3067 days
8.7
TCGA-EY-A547-01A
0 years, female, black or african american, stage:Stage IA, alive, 545 days
8.5
TCGA-AX-A3G8-01A
0 years, female, white, stage:Stage IA, alive, 36 days
8.0
TCGA-AX-A3FX-01A
0 years, female, white, stage:Stage IIB, dead, 1333 days
7.8
TCGA-AJ-A3BD-01A
0 years, female, white, stage:Stage IIIC, alive, 1039 days
7.8
TCGA-EO-A3AZ-01A
0 years, female, stage:Stage IB, alive, 826 days
6.9
TCGA-SJ-A6ZJ-01A
0 years, female, black or african american, stage:Stage IB, alive, 556 days
6.7
TCGA-A5-A2K5-01A
0 years, female, white, stage:Stage IA, alive, 752 days
5.1
TCGA-AJ-A3BI-01A
0 years, female, white, stage:Stage IA, alive, 575 days
4.5
TCGA-QS-A5YQ-01A
0 years, female, black or african american, stage:Stage IIIA, alive, 759 days
4.0
TCGA-H5-A2HR-01A
0 years, female, black or african american, stage:Stage IB, alive, 53 days
3.7
TCGA-BS-A0V7-01A
0 years, female, native hawaiian or other pacific islander, stage:Stage IB, alive, 1934 days
3.4
TCGA-DF-A2L0-01A
0 years, female, stage:Stage IIIC, dead, 788 days
3.3
TCGA-EO-A3AY-01A
0 years, female, stage:Stage IB, alive, 1158 days
2.8
TCGA-AX-A1C7-01A
0 years, female, white, stage:Stage IB, alive, 1054 days
2.2
TCGA-BS-A0V4-01A
0 years, female, white, stage:Stage IB, alive, 1810 days
1.5
TCGA-AX-A3G7-01A
0 years, female, white, stage:Stage IVB, alive, 9 days
0.0
TCGA-5S-A9Q8-01A
0 years, female, black or african american, stage:Stage IIIA, alive, 313 days
0.0
TCGA-FI-A2EY-01A
0 years, female, white, stage:Stage IIIA, dead, 880 days
0.0
Show allShow less
ENDOMETRIOID ADENOCARCINOMA - Protein relative expression (CPTAC)
Number of samples
153
Samples
Sample ID
Sample type
nRPX
CPT0002560003
Tumor
1.4
CPT0018960003
Tumor
1.1
CPT0064210003
Tumor
0.9
CPT0063380003
Tumor
0.9
CPT0000980012
Tumor
0.8
CPT0002430011
Tumor
0.7
CPT0000730011
Tumor
0.7
CPT0001140003
Tumor
0.6
CPT0070330004
Tumor
0.6
CPT0077650003
Tumor
0.5
CPT0027520003
Tumor
0.5
CPT0080030003
Tumor
0.4
CPT0093280003
Tumor
0.4
NX9
Normal
0.4
CPT0001910016
Tumor
0.4
CPT0075900003
Tumor
0.4
CPT0066620003
Tumor
0.3
CPT0075380003
Tumor
0.3
CPT0002080011
Tumor
0.3
CPT0007600003
Tumor
0.3
CPT0064290004
Tumor
0.3
CPT0080880003
Tumor
0.3
NX17
Normal
0.3
CPT0017930001
Normal
0.3
CPT0063890003
Tumor
0.2
CPT0080980003
Tumor
0.2
CPT0027650003
Tumor
0.2
CPT0093290000
Normal
0.2
CPT0016490003
Tumor
0.2
CPT0016370003
Tumor
0.2
CPT0007100003
Tumor
0.2
CPT0073460001
Normal
0.2
NX16
Normal
0.2
CPT0010610003
Tumor
0.2
NX2
Normal
0.2
CPT0022830003
Tumor
0.2
CPT0070380004
Tumor
0.2
CPT0063790003
Tumor
0.2
CPT0002130003
Tumor
0.2
NX5
Normal
0.2
CPT0073730003
Tumor
0.2
CPT0064930004
Tumor
0.2
CPT0026770003
Tumor
0.2
NX6
Normal
0.1
CPT0076160003
Tumor
0.1
NX8
Normal
0.1
NX14
Normal
0.1
NX7
Normal
0.1
CPT0027420003
Tumor
0.1
CPT0026430003
Tumor
0.1
CPT0017870003
Tumor
0.1
CPT0027970003
Tumor
0.1
CPT0026780001
Normal
0.1
CPT0001300009
Tumor
0.1
CPT0076860003
Tumor
0.1
CPT0080300003
Tumor
0.1
CPT0001460012
Tumor
0.1
CPT0001420009
Tumor
0.0
CPT0023640001
Normal
0.0
CPT0016530001
Normal
0.0
CPT0079650003
Tumor
0.0
CPT0027020001
Normal
0.0
NX10
Normal
0.0
CPT0027320003
Tumor
0.0
CPT0002630003
Tumor
0.0
CPT0073530001
Normal
0.0
CPT0001850012
Tumor
0.0
CPT0002500011
Tumor
0.0
CPT0116630003
Tumor
0.0
CPT0073520003
Tumor
0.0
CPT0027120003
Tumor
0.0
NX4
Normal
0.0
NX15
Normal
0.0
CPT0062940003
Tumor
0.0
CPT0063250003
Tumor
0.0
CPT0080610003
Tumor
0.0
CPT0076500003
Tumor
0.0
CPT0064150004
Tumor
0.0
CPT0016830003
Tumor
0.0
CPT0064320001
Normal
0.0
CPT0076680003
Tumor
0.0
CPT0026530003
Tumor
0.0
NX18
Normal
-0.1
CPT0064240001
Normal
-0.1
CPT0063670003
Tumor
-0.1
CPT0023630003
Tumor
-0.1
CPT0063090003
Tumor
-0.1
CPT0026540001
Normal
-0.1
CPT0077660001
Normal
-0.1
NX12
Normal
-0.1
CPT0007660001
Normal
-0.1
CPT0022530003
Tumor
-0.1
CPT0113690003
Tumor
-0.1
NX13
Normal
-0.1
CPT0080990001
Normal
-0.1
CPT0063260001
Normal
-0.1
CPT0026660001
Normal
-0.1
CPT0097710003
Tumor
-0.1
CPT0080890001
Normal
-0.1
CPT0064950001
Normal
-0.1
CPT0078610003
Tumor
-0.2
CPT0073450003
Tumor
-0.2
CPT0027130001
Normal
-0.2
CPT0027810003
Tumor
-0.2
CPT0078710004
Tumor
-0.2
CPT0063110001
Normal
-0.2
NX3
Normal
-0.2
CPT0026650003
Tumor
-0.2
CPT0011020003
Normal
-0.2
NX11
Normal
-0.2
CPT0026030004
Tumor
-0.3
CPT0009980003
Tumor
-0.3
CPT0026270003
Tumor
-0.3
CPT0023810003
Tumor
-0.3
CPT0078320004
Tumor
-0.3
CPT0002010011
Tumor
-0.3
CPT0015520003
Tumor
-0.3
CPT0021650003
Tumor
-0.3
CPT0002450001
Normal
-0.4
CPT0080700003
Tumor
-0.4
CPT0016940003
Tumor
-0.4
CPT0077780001
Normal
-0.4
CPT0001470001
Normal
-0.4
CPT0022620003
Tumor
-0.4
CPT0016220003
Tumor
-0.4
CPT0070260003
Tumor
-0.5
NX1
Normal
-0.5
CPT0016260003
Tumor
-0.5
CPT0020530003
Tumor
-0.5
CPT0097010003
Tumor
-0.5
CPT0080400003
Tumor
-0.5
CPT0075940001
Normal
-0.5
CPT0063900001
Normal
-0.5
CPT0027430001
Normal
-0.5
CPT0077770003
Tumor
-0.5
CPT0011000003
Tumor
-0.6
CPT0024130003
Tumor
-0.6
CPT0116550004
Tumor
-0.6
CPT0002210011
Tumor
-0.7
CPT0116570003
Normal
-0.7
CPT0078360001
Normal
-0.7
CPT0010430003
Tumor
-0.8
CPT0019840003
Tumor
-1.0
CPT0018570003
Tumor
-1.1
CPT0010260003
Tumor
-1.1
CPT0010820003
Tumor
-1.4
CPT0080620001
Normal
-1.4
CPT0018790003
Tumor
-1.5
CPT0022850001
Normal
-1.5
CPT0079570003
Tumor
N/A
CPT0078880003
Tumor
N/A
CPT0097730003
Tumor
N/A
CPT0000820012
Tumor
N/A
Show allShow less
UTERINE CORPUS ENDOMETRIAL CARCINOMA - Protein relative expression (CPTAC)
Number of samples
160
Samples
Sample ID
Sample type
nRPX
CPT0111880003
Tumor
1.2
CPT0197250003
Tumor
1.0
CPT0117300003
Tumor
1.0
CPT0248000003
Tumor
1.0
NX033
Normal
1.0
CPT0182290003
Tumor
0.9
CPT0182380004
Tumor
0.9
CPT0181960004
Tumor
0.9
CPT0238260003
Tumor
0.8
CPT0288750003
Tumor
0.8
CPT0097300003
Tumor
0.8
CPT0117230003
Tumor
0.7
NX036
Normal
0.7
CPT0182070004
Tumor
0.7
CPT0117440003
Tumor
0.7
CPT0117560003
Tumor
0.6
CPT0182340004
Tumor
0.6
NX037
Normal
0.6
CPT0265110003
Tumor
0.6
CPT0115530003
Tumor
0.6
CPT0100100003
Tumor
0.5
CPT0116010004
Tumor
0.5
CPT0187960004
Tumor
0.5
CPT0288830003
Tumor
0.5
CPT0112780003
Tumor
0.5
CPT0083580003
Tumor
0.5
CPT0247940003
Tumor
0.5
NX038
Normal
0.5
CPT0099910003
Tumor
0.5
CPT0234080003
Tumor
0.5
CPT0244470003.1
Tumor
0.5
CPT0247970003
Tumor
0.4
CPT0116340004
Tumor
0.4
CPT0225010003
Tumor
0.4
CPT0095190003
Tumor
0.4
CPT0116940003
Tumor
0.4
CPT0113910003
Tumor
0.4
CPT0129640003
Tumor
0.4
CPT0158520008
Tumor
0.4
CPT0182210004
Tumor
0.4
NX022
Normal
0.4
CPT0116140004
Tumor
0.4
CPT0190700008
Tumor
0.4
CPT0172200008
Tumor
0.4
CPT0111950003
Tumor
0.4
CPT0188610003
Tumor
0.4
CPT0171090008
Tumor
0.4
CPT0117510003
Tumor
0.4
NX032
Normal
0.4
CPT0196790004
Tumor
0.4
CPT0100010003
Tumor
0.3
CPT0095230003
Tumor
0.3
CPT0095100003
Tumor
0.3
CPT0188480004
Tumor
0.3
CPT0092690003
Tumor
0.3
CPT0182150003
Tumor
0.3
CPT0095130004
Tumor
0.3
CPT0186900008
Tumor
0.3
CPT0188710003
Tumor
0.3
CPT0181610003
Tumor
0.3
CPT0181540008
Tumor
0.3
CPT0099050003
Tumor
0.3
CPT0093170003
Tumor
0.3
CPT0092460003
Tumor
0.3
CPT0115000004
Tumor
0.3
CPT0086090003
Tumor
0.3
CPT0247910003
Tumor
0.3
NX034
Normal
0.3
CPT0087260003
Tumor
0.2
CPT0203040008
Tumor
0.2
CPT0104820003
Tumor
0.2
CPT0128770003
Tumor
0.2
CPT0116710003
Tumor
0.2
CPT0091910003
Tumor
0.2
CPT0128610003
Tumor
0.2
CPT0086490003
Tumor
0.2
CPT0133400008
Tumor
0.2
CPT0181320003
Tumor
0.2
NX023
Normal
0.2
CPT0114340003
Tumor
0.2
CPT0188370003
Tumor
0.2
NX031
Normal
0.2
CPT0089600003
Tumor
0.2
CPT0108750003
Tumor
0.2
CPT0244510003
Tumor
0.2
CPT0127700003
Tumor
0.2
CPT0116250004
Tumor
0.1
CPT0136280003
Tumor
0.1
CPT0115470003
Tumor
0.1
CPT0186720008
Tumor
0.1
CPT0092860003
Tumor
0.1
CPT0091720003
Tumor
0.1
CPT0098920003
Tumor
0.1
CPT0096010003
Tumor
0.1
CPT0159220008
Tumor
0.1
CPT0097440003
Tumor
0.1
CPT0088140003
Tumor
0.1
CPT0091780003
Tumor
0.1
CPT0091990003
Tumor
0.1
CPT0129080003
Tumor
0.1
CPT0188270004
Tumor
0.1
NX027
Normal
0.1
CPT0161590008
Tumor
0.1
CPT0129520003
Tumor
0.0
CPT0098270003
Tumor
0.0
CPT0127610003
Tumor
0.0
CPT0104690003
Tumor
0.0
CPT0113330003
Tumor
0.0
NX025
Normal
0.0
CPT0111810003
Tumor
0.0
CPT0133600003
Tumor
0.0
CPT0095880003
Tumor
0.0
CPT0182020004
Tumor
0.0
CPT0181670008
Tumor
0.0
NX029
Normal
0.0
CPT0127980003
Tumor
0.0
CPT0134310008
Tumor
-0.1
CPT0095280003
Tumor
-0.1
CPT0111720003
Tumor
-0.1
CPT0113430004
Tumor
-0.1
CPT0265300003
Tumor
-0.1
NX035
Normal
-0.1
NX028
Normal
-0.1
NX020
Normal
-0.1
CPT0226810003
Tumor
-0.1
CPT0133770008
Tumor
-0.1
CPT0117010004
Tumor
-0.1
NX024
Normal
-0.2
CPT0117370004
Tumor
-0.2
CPT0114100003
Tumor
-0.2
CPT0226860003
Tumor
-0.2
CPT0181750004
Tumor
-0.2
CPT0126000003
Tumor
-0.2
CPT0159110003
Tumor
-0.2
CPT0113060003
Tumor
-0.2
CPT0137140008
Tumor
-0.2
CPT0134500003
Tumor
-0.2
CPT0275270003.1
Tumor
-0.2
CPT0203150008
Tumor
-0.3
CPT0188030003
Tumor
-0.3
CPT0181810004
Tumor
-0.3
CPT0203250008
Tumor
-0.3
NX019
Normal
-0.4
CPT0112910003
Tumor
-0.4
NX021
Normal
-0.4
CPT0113850003
Tumor
-0.4
CPT0188100004
Tumor
-0.4
CPT0128370003
Tumor
-0.5
CPT0188190004
Tumor
-0.5
CPT0186010004
Tumor
-0.6
CPT0128960003
Tumor
-0.6
CPT0211120004
Tumor
-0.6
NX030
Normal
-0.7
CPT0247880003
Tumor
-0.9
CPT0174890008
Tumor
-0.9
CPT0172460008
Tumor
-1.2
CPT0186560008
Tumor
-1.5
NX026
Normal
-1.7
CPT0244470003
Tumor
N/A
CPT0275270003
Tumor
N/A
Show allShow less
ENDOMETRIAL CANCER - Protein expressioni
A mouse-over function shows sample information and annotation data. Click on an image to view it in a full screen mode. Samples can be filtered based on level of antibody staining by selecting one or several of the following categories: high, medium, low and not detected. The assay and annotation is described here.
Note that samples used for immunohistochemistry by the Human Protein Atlas do not correspond to samples in the TCGA dataset.
Antibody stainingi
Antibody staining in the annotated cell types in the current human tissue is reported as not detected, low, medium, or high, based on conventional immunohistochemistry profiling in selected tissues. This score is based on the combination of the staining intensity and fraction of stained cells.
Each image is clickable and will lead to virtual microscopy that enables deeper exploration of all samples and also displays staining intensity scores, fraction scores and subcellular localization as well as patient and tissue information for each sample.
The Human Protein Atlas project is funded
